BMO Capital Maintains Outperform on Chemours, Lowers Price Target to $18
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.
BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.